Medical products company Hill-Rom is using its $2 billion acquisition of patient monitoring and diagnostics player Welch Allyn to decrease its reliance on sales of large, acute-care capital equipment--which are highly subject to pressure from macroeconomic changes.
Actavis may have changed its name to Allergan this week, but nothing has changed about its penchant for dealmaking. The newly bulked-up pharma struck again Wednesday, inking a pact for Kythera Biopharmaceuticals.
The freshly rebranded Allergan is planning to spend $2.1 billion on Kythera, maker of an injection to reduce chin fat, in a deal designed to bolster the company's strength in aesthetics.
Mylan can breathe a little easier knowing it has support from its largest shareholder in its quest to pick up Perrigo. After all, it's not just a big buyout at stake--but the opportunity to thwart its own unwanted takeover by generics rival Teva.
Respiratory biotech Pulmatrix has completed its nontraditional path to the public markets, closing a merger with upstart Ruthigen to inherit a Nasdaq listing, at the same time banking $10 million and partnering up with generics giant Mylan.
In their last letter to Mylan Chairman Robert Coury, Teva's leaders made it explicitly clear: They're proceeding down their takeover path whether Mylan likes it or not. And they took another step forward this week, further hiking Teva's stake in their target.
Months after changing hands in a $128 million deal, CRO Synexus is gearing up for growth, looking to expand its geographic reach and areas of expertise.
Industry watchers are keeping a close eye on Bayer's big divestment plans, which involve jettisoning its plastics unit before mid-2016. But meanwhile, it's getting a jump on the slim-down process with the sale of its diabetes care business.
A rash of unnamed-source reports claim Receptos has shaken off multibillion-dollar advances from some of the world's biggest drugmakers, sending the San Diego biotech's shares ever higher as it advances its autoimmune treatment.
The long-rumored sale of Bayer's diabetes device business to Panasonic Healthcare looks like it's finally coming to fruition after speculation stretching back at least to early this year. Bayer has said it will sell its Diabetes Care business to Panasonic Healthcare for €1.022 billion ($1.16 billion) in a deal expected to close during the first quarter of next year.